

16/02/2009

Antisoma reports half-year results

London, UK, and Cambridge, MA: 16 February 2009 Antisoma plc (LSE: ASM; USOTC: ATSMY) announces its interim financial information for the period ended 31 December 2008.

Highlights

First product approval from FDA

Oral fludarabine approved for chronic lymphocytic leukaemia

Pivotal phase III programmes advanced

Phase III trial of ASA404 in first-line lung cancer ongoing

Phase III trial of ASA404 in second-line lung cancer initiated

Phase III trial of AS1413 in leukaemia expanded

Strong partnership with Novartis on ASA404

Lung cancer programme extended to second-line setting

Clinical development to expand into breast cancer

Supportive phase II data on key programmes

Long-term follow-up data from ASA404 and AS1413 trials

Positive interim data on AS1411 in acute myeloid leukaemia

New phase II trials initiated

AS1411 in renal cancer, AS1402 in breast cancer

Financial highlights

Six month revenues of GBP 5.5 million (H1 2007: GBP 16.5 million)

Loss after tax of GBP 5.0 million (H1 2007: profit after tax of GBP 6.2 million)

Cash resources at 31 December 2008 of GBP 52.7 million (31 December 2007: GBP 50.4 million)

Glyn Edwards, CEO of Antisoma, said: "We have made substantial progress during this period, with our first product approval from the FDA and gathering momentum on our two key phase III development programmes, as well as very interesting initial findings from our phase II trial of AS1411 in leukaemia. We look forward to further developments in the first half of this year, notably a commercialisation deal for our approved product oral fludarabine and the final data from the AS1411 trial."

Eric Dodd, Antisoma's CFO, added: "Our financial results show that we are well placed to continue investment in our drug pipeline, with current cash resources sufficient to take our key programmes through mid-2010. With the divestment or partnering of oral fludarabine, we expect to extend this to mid-2011."

A webcast and conference call will be held today at 9.30 am GMT. The webcast can be accessed via Antisoma's website at www.antisoma.com and the call by dialling +44 (0)20 8609 1435 (UK toll-free 0808 109 1498; US toll-free 1866 793 4279) and using the participant PIN code [965983#]. A recording of the webcast will also be available afterwards on Antisoma's website.

Enquiries:

Glyn Edwards
Chief Executive Officer

Eric Dodd

Daniel Elger VP, Marketing and Communications	+44 (0)7909 915 068
Mark Court, Lisa Baderoon, Rebecca Skye Dietrich Buchanan Communications	+44 (0)20 7466 5000
Brian Korb The Trout Group	+1 212 477 9007

Except for the historical information presented, certain matters discussed in this statement are forward looking statements that are subject to a number of risks and uncertainties that could cause actual results to differ materially from results, performance or achievements expressed or implied by such statements. These risks and uncertainties may be associated with product discovery and development, including statements regarding the Group's clinical development programmes, the expected timing of clinical trials and regulatory filings. Such statements are based on management's current expectations, but actual results may differ materially.

[View the full press release in PDF format \(96.3 KB, document opens in a new window\)](#)

[^ Back to top](#)

[centre](#) | [Media centre](#) | [Partnering](#) | [Careers](#) | [Contact us](#) | [Site map](#) | [Alert service](#) | [Disclaimer](#) | [Accessibility](#)